For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 1-9 results of 9
Urinary Cancer

AFT-19

Official Title: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Study Purpose: To compare progression free survival and overall survival of the standard hormone therapy degarelix verses  degarelix and apalutamide versus degarelix, apalutamide, abiraterone, and prednisone.
Status: Recruiting
Urinary Cancer

Alliance A031102

Official Title: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Study Purpose: To determine if giving high dose chemotherapy and having a stem cell transplant will prevent or lengthen the time the time to recurrence when compared to the usual treatment of chemotherapy.  
Status: Recruiting
Urinary Cancer

Alliance A031702

Official Title: Testing the effectiveness of two immunotherapy drugs (nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors
Study Purpose: To test the good and bad effects of the drugs cabozantinib, nivolumab, and ipilimumab in rare genitourinary cancers that have no standard treatment options. The doctors hope to learn if the study drugs will stabilize or shrink the cancer.
Status: Suspended
Urinary Cancer

Alliance A031704

Official Title: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer
Study Purpose: To see how well nivolumab and ipilimumab, followed by nivolumab versus cabozantinib and nivolumab, work in treating renal cell cancer that is untreated and has spread to other parts of the body.
Status: Recruiting
Urinary Cancer

Alliance A222001

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Study Purpose: To test whether a low or high dose of oxybutynin can reduce hot flashes. 
Status: Recruiting
Urinary Cancer

CTSU S1931

Official Title: Comparing The Outcome Of Immunotherapy-Based Drug Combination Therapy With Or Without Surgery To Remove The Kidney In Metastatic Kidney Cancer
Study Purpose: To compare Standard Systemic Therapy alone to Standard Systemic Therapy plus surgery to remove all or part of the kidney with tumor.
Status: Recruiting
Urinary Cancer

NRG GU002

Official Title: Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Study Purpose: To assess the impact Docetaxel has on the survival of patients who received radiation and hormone therapy after prostate removal
Status: Recruiting
Urinary Cancer

SWOG S1802

Official Title: Comparing the Treatment Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy in Combination with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Study Purpose: To compare the effects, good and/or bad, of adding prostate removal surgery or radiation therapy to standard therapy which is used to treat prostate cancer.
Status: Recruiting
Urinary Cancer

SWOG S1806

Official Title: Testing Combined Chemotherapy and Radiation Therapy With and Without the Use of Atezolizumab Immunotherapy in Muscle Invasive Bladder Cancer
Study Purpose: To compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of the immunotherapy drug atezolizumab, used to treat bladder cancer.
Status: Recruiting